Inactive Instrument

Press Releases Sienna Biopharmaceuticals, Inc. Other OTC

Equities

SNNAQ

US82622H1086

Press Releases

Unlock all the news: Be the first to know and act before the market!

SIENNA BIOPHARMACEUTICALS, INC. : Other Events (form 8-K)	19-12-11	AQ
Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures	19-11-14	GL
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice	19-11-14	GL
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair	19-10-07	GL
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding	19-09-17	GL
Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strategic Alternatives	19-08-05	GL
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference	19-06-20	GL
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology	19-06-10	GL
Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results	19-05-08	GL
Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations	19-03-21	GL
Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference	19-03-05	GL
Sienna Biopharmaceuticals Prices Public Offering of Common Stock	19-02-20	GL
Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock	19-02-19	GL
Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System	19-02-08	GL
Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference	19-01-02	GL
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference	18-12-06	GL
Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019	18-12-03	GL
Sienna Biopharmaceuticals® Reports Third Quarter 2018 Financial Results	18-11-08	GL
Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2	18-08-27	GL
Sienna Biopharmaceuticals Reports Second Quarter 2018 Financial Results	18-08-09	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sienna Biopharmaceuticals, Inc. Other OTC

Equities

SNNAQ

US82622H1086

Press Releases

Filters